Article
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
The pharmacogenomics journal - 1 Oct 2008
Filopanti M, Barbieri A M, Angioni A R, Colao A, Gasco V, Grottoli S, Peri A, Baglioni S, Fustini M F, Pigliaru F, Monte P D, Borretta G, Ambrosi B, Jaffrain-Rea M L, Gasperi M, Brogioni S, Cannavò S, Mantovani G, Beck-Peccoz P, Lania A, Spada A
Abstract excerpt
Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). The mechanisms responsible for resistance to CB remain largely unknown. To assess the association of DRD2 with sensitivity to CB, TaqI-A1/A2, TaqI-B1/B2, HphI-G/T and NcoI-C/T genotypes were determined in a cross-sectional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.